PCL/chitosan/Zn-doped nHA electrospun nanocomposite scaffold promotes adipose derived stem cells adhesion and proliferation.
Ghorbani FM., Kaffashi B., Shokrollahi P., Seyedjafari E., Ardeshirylajimi A.
Laboratory Study, published in Carbohydr Polym (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Carbohydr Polym (2014)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25542118
- DOI
- 10.1016/j.carbpol.2014.10.071
- Citations
- 93
Abstract (original English)
Chitosan (Ch), and poly(ɛ-caprolactone) (PCL), widely used as biomaterials with desirable properties for tissue engineering applications, were both blended with zinc-doped hydroxyapatite nanoparticles(nZnHA) and electrospun into nanofibrous scaffolds using formic acid/acetic acid. The rationale behind this study was to demonstrate that presence of small quantities of Zn(2+) ions doped in HA nanoparticles can improve biocompatibility of PCL/Ch blends. SEM observation revealed that average fiber diameter was increased from about 136 nm for a PCL/Ch blend, to around 210 nm for PCL/Ch/nZnHA nanocomposite. PCL/Ch/nZnHA scaffolds offered higher elastic modulus (about 3-fold) and tensile strength (nearly 1.5-fold) than the corresponding PCL/Ch scaffolds. In-vitro biocompatibility studies using human adipose derived stem cells (hAD-MSCs), demonstrated that the presence of only 5 wt% nZnHA in PCL/Ch/nZnHA nanocomposites enhanced hAD-MSCs' attachment compared to PCL/Ch and PCL/Ch/nHA. Finally, hAD-MSCs proliferation occurred at significantly higher rates of 1.5, 1.3 and 1.2 times on PCL/Ch/nZnHA scaffold compared to PCL, PCL/Ch and PCL/Ch/nHA, respectively.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.